Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | BMP2 | P12643 | 1/20 | 0.30 |
| ▸ | VEGFA | P15692 | 1/20 | 0.30 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.30 |
| ▸ | SHH | Q15465 | 1/20 | 0.30 |
| ▸ | PTN | P21246 | 1/20 | 0.30 |
| ▸ | MDK | P21741 | 1/20 | 0.30 |
| ▸ | BDNF | P23560 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371574 | 0.87 | TLR4 (0.51) | TLR4MAPK1 | |
| SCHEMBL12371571 | 0.84 | TLR4 (0.43) | TLR4MAPK1 | |
| SCHEMBL13248408 | 0.76 | HPSE (0.34) | CA1CA2CA9SELPVEGFA | |
| SCHEMBL30063190 | 0.74 | CYP3A4 (0.32) | CA1CA2CA9 | |
| SCHEMBL12371581 | 0.74 | MAPK1 (0.53) | TLR4CA1CA2CA9MAPK1 | |
| SCHEMBL12762999 | 0.74 | MAPK1 (0.53) | TLR4CA1CA2CA9MAPK1 | |
| SCHEMBL12371570 | 0.73 | TLR4 (0.34) | TLR4 | |
| SCHEMBL4158124 | 0.71 | CA2 (0.36) | CA1CA2CA9 | |
| SCHEMBL13697309 | 0.71 | CA2 (0.36) | CA1CA2CA9 | |
| SCHEMBL14765411 | 0.71 | CA2 (0.36) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994154-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | Ersai R&D Management Co., Ltd. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-09-09 | — | — | US | disclosed |
| US-7737129-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | EISAI CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | LIPG, FUT6, UGCG | TLR4 94/4885CA1 3666/4885CA2 4082/4885 |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | LIPG, FUT6, UGCG | TLR4 94/4885CA1 3666/4885CA2 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.